rethinkTHC Search
Menu
Study breakdown

Consumer Experiences with Delta-8-THC: Medical Uses and Comparisons to Delta-9-THC

evidence
The takeaway

Consumers reported using delta-8-THC for medical purposes and as a pharmaceutical substitute, describing it as milder than delta-9-THC with fewer adverse effects.

Cannabis consumers, healthcare providers, regulators, and researchers studying minor cannabinoids.

Milder than delta-9

Consumers described delta-8-THC as producing a milder high with fewer negative side effects than delta-9-THC

What the researchers found

Survey respondents reported using delta-8-THC for pain, anxiety, and other medical conditions, often as a substitute for pharmaceutical medications, and described it as producing a milder high with fewer negative side effects compared to delta-9-THC.

Why it matters

Delta-8-THC became widely available across most US states in late 2020, yet consumer experiences and motivations for use have been poorly documented, leaving a gap in evidence for regulation and clinical guidance.

The numbers in context

Delta-8-THC products became widely available in most of the United States in late 2020, becoming a significant revenue source for hemp processing companies.

How the study worked

Consumer survey examining experiences, motivations, and self-reported effects of delta-8-THC use.

Who was studied

Consumers who have used delta-8-THC products in the United States.

What this study cannot tell us

Self-selected survey sample may overrepresent positive experiences; self-reported effects lack clinical verification; product quality and actual delta-8 content were not verified.

How to read the evidence

Consumer survey provides self-reported experiential data; useful for understanding user perspectives but not clinical evidence.

When this study was published

Timely research capturing early consumer experiences with a rapidly expanding product category.

The bigger picture

The delta-8 market represents a massive natural experiment in cannabinoid consumer behavior, emerging from a regulatory loophole in the 2018 Farm Bill that classified hemp-derived products differently from marijuana.

Replication

Among the first systematic surveys of delta-8 consumer experiences; findings align with anecdotal reports.

Funding

Not specified

Conflicts of interest

Not specified

Questions still open

  • How do delta-8 and delta-9 THC differ pharmacologically?
  • What are the long-term safety implications of delta-8 use?
  • Should delta-8 products be regulated differently than delta-9?

Read the original research

Consumer Experiences with Delta-8-THC: Medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC.

Cannabis and cannabinoid research, 8(1), 166-173

Citation

Kruger, Daniel J; Kruger, Jessica S. (2023). Consumer Experiences with Delta-8-THC: Medical Use, Pharmaceutical Substitution, and Comparisons with Delta-9-THC.. Cannabis and cannabinoid research, 8(1), 166-173. https://doi.org/10.1089/can.2021.0124